Tonix Pharmaceuticals Holding Corp. (TNXP)
$13.47-$0.09 (-0.67%) Today
Carolyn E. Taylor - Director
Seth Lederman - OfficerSeth Lederman - OfficerSeth Lederman - OfficerCarolyn E. Taylor - DirectorTonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 12,415 | $145K |
| Other acquisition / disposition | 1 | 1,453 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from May 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Richard H. Bagger - Director | Open-market purchase | Common Stock, par value $0.001 | 1,000 | $12.60 | $13K | |
 Bradley Saenger - Officer | Other | Common Stock, $0.001 par value | 1,453 | $10.91 | $16K | |
| Carolyn E. Taylor - Director | Open-market purchase | Common Stock, $0.001 par value | 1,415 | $10.55 | $15K | |
| Richard Newcomb Stillwell - Director | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $11.65 | $58K | |
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $11.79 | $59K | |
| Richard Newcomb Stillwell - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| Adeoye Y. Olukotun - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
 Margaret Smith Bell - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| James Randolph Hunter Jr. - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| James Treco - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| David L. Grange - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| Richard H. Bagger - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| Carolyn E. Taylor - Director | Grant or award | Stock Option | 22,700 | $0.00 | - | |
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $12.62 | $63K | |
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 15,000 | $14.89 | $223K | |
| Jessica Edgar Morris - Officer | Grant or award | Stock Option | 39,012 | $0.00 | - | |
| Jessica Edgar Morris - Officer | Grant or award | Stock Option | 39,011 | $0.00 | - | |
| Bradley Saenger - Officer | Grant or award | Stock Option | 39,012 | $0.00 | - | |
| Bradley Saenger - Officer | Grant or award | Stock Option | 39,011 | $0.00 | - | |
 Gregory M. Sullivan - Officer | Grant or award | Stock Option | 39,012 | $0.00 | - | |
| Gregory M. Sullivan - Officer | Grant or award | Stock Option | 39,011 | $0.00 | - | |
 Siobhan Fogarty - Officer | Grant or award | Stock Option | 39,012 | $0.00 | - | |
| Siobhan Fogarty - Officer | Grant or award | Stock Option | 39,011 | $0.00 | - | |
| Seth Lederman - Officer | Grant or award | Stock Option | 134,504 | $0.00 | - | |
| Seth Lederman - Officer | Grant or award | Stock Option | 134,503 | $0.00 | - | |
| Carolyn E. Taylor - Director | Open-market purchase | Common Stock, par value $0.001 | 418 | $36.03 | $15K | |
| James Treco - Director | Open-market purchase | Common Stock, par value $0.001 | 250 | $36.00 | $9K | |
| David L. Grange - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
| Adeoye Y. Olukotun - Director | Grant or award | Stock Option | 10,000 | $0.00 | - |
Tonix Pharmaceuticals Holding Corp. (TNXP) had 5 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for TNXP runs to 24 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
4 insider purchases of TNXP were filed in the last 90 days, totaling $145K.
No insider sales of TNXP were filed in the last 90 days.
This page tracks TNXP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TNXP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
